HI-Bio Revenue and Competitors
Estimated Revenue & Valuation
- HI-Bio's estimated annual revenue is currently $4.8M per year.
- HI-Bio's estimated revenue per employee is $77,500
Employee Data
- HI-Bio has 62 Employees.
- HI-Bio grew their employee count by 35% last year.
HI-Bio's People
Name | Title | Email/Phone |
---|---|---|
1 | Senior Executive Assistant To CEO | Reveal Email/Phone |
2 | Founder & CEO | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | SVP, Development Operations | Reveal Email/Phone |
5 | VP Biometrics | Reveal Email/Phone |
6 | VP, Biomarker and Bioanalytical Sciences | Reveal Email/Phone |
7 | VP, Finance | Reveal Email/Phone |
8 | VP, Chemistry Manufacturing and Controls | Reveal Email/Phone |
9 | Sr. Director | Reveal Email/Phone |
10 | Director | Reveal Email/Phone |
HI-Bio Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is HI-Bio?
Human Immunology Biosciences (HI-Bio) is leading clinical immunology into its next chapter with therapies that target cellular drivers of disease. HI-Bio uses a precision medicine approach to deliver therapies for patients with the auto-immune, allergic and inflammatory diseases that can together be referred to as immune-mediated diseases (IMDs).
keywords:N/AN/A
Total Funding
62
Number of Employees
$4.8M
Revenue (est)
35%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $5.6M | 62 | 13% | N/A |
#2 | $3.5M | 62 | 3% | N/A |
#3 | $15M | 62 | 5% | N/A |
#4 | $8.1M | 62 | 5% | N/A |
#5 | $9.8M | 62 | -9% | N/A |